Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

BACKGROUND: Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion) on day 1 every 3 weeks (q3wk), and obtained pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Calvo, E., Moreno, V., Flynn, M., Holgado, E., Olmedo, M. E., Lopez Criado, M. P., Kahatt, C., Lopez-Vilariño, J. A., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Soto Matos-Pita, A., Forster, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834091/
https://www.ncbi.nlm.nih.gov/pubmed/28961837
http://dx.doi.org/10.1093/annonc/mdx357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834091/
https://www.ncbi.nlm.nih.gov/pubmed/28961837
http://dx.doi.org/10.1093/annonc/mdx357

Ejemplares similares